The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Refractory Plaque Psoriasis: Biologic Treatment Algorithm

Step-wise selection and switching among TNF, IL-17, IL-23, and IL-12/23 inhibitors for moderate-to-severe plaque psoriasis with comorbidity-driven personalization.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dermatoloji department. Book Appointment →

What is Refractory Plaque Psoriasis: Biologic Treatment Algorithm?

Plaque psoriasis is a chronic immune-mediated disease driven by TNF-α, IL-23/IL-17 axis, with characteristic erythematous scaly plaques on extensor surfaces, scalp, and nails. Disease severity is graded by Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI).

Refractory disease is defined as inadequate response to optimized topical therapy plus at least one systemic therapy or phototherapy, with persistent moderate-to-severe disease (PASI ≥10, BSA >10%, DLQI >10) or special location involvement (face, palms, soles, genitals, scalp) impacting quality of life.

Biologic landscape (2024): TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab); IL-12/23 inhibitor (ustekinumab); IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab); IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab, mirikizumab). Selection is increasingly personalized.

Symptoms

Persistent or recurrent moderate-to-severe plaque psoriasis (PASI ≥10)
Special site involvement: scalp, face, palms, soles, genitals, nails
Inadequate response to topical corticosteroids, vitamin D analogs, methotrexate, cyclosporine, or phototherapy
Significant impact on quality of life (DLQI >10)
Comorbid psoriatic arthritis (joint pain, dactylitis, enthesitis)
Comorbid metabolic syndrome, cardiovascular disease, NAFLD
Inflammatory bowel disease (Crohn's, UC) — comorbid

Risk Factors

Family history of psoriasis (HLA-Cw6, IL-23R polymorphisms)
Severe widespread disease at presentation
Early-onset psoriasis (type I, before age 40)
Smoking, obesity (BMI >30), metabolic syndrome
Streptococcal pharyngitis (guttate trigger)
Comorbid inflammatory diseases (psoriatic arthritis, IBD, MS)
Stress, alcohol, certain medications (lithium, beta-blockers, IFN, antimalarials)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Refractory psoriasis after topical and systemic therapy trials
  • PASI ≥10 or DLQI >10 with significant life impact
  • Joint symptoms (psoriatic arthritis development)
  • Special site involvement causing functional or psychosocial distress
  • Dermatology referral for biologic candidacy assessment

Treatment Methods

01
Pre-biologic workup: TB screening (IGRA, chest X-ray), hepatitis B/C, HIV, CBC, LFTs, vaccination status (live vaccines contraindicated on biologics — give pre-treatment), pregnancy planning discussion
02
First-line biologic by comorbidity: psoriatic arthritis → TNF inhibitor (adalimumab, etanercept) or IL-17 (secukinumab, ixekizumab) or IL-23 (guselkumab); IBD → ustekinumab, risankizumab (avoid IL-17 — exacerbates IBD); heart failure NYHA III/IV → avoid TNF inhibitors
03
Highest efficacy by PASI 90 at week 16: bimekizumab (~85%), risankizumab (~75%), ixekizumab (~75%), guselkumab (~73%), brodalumab (~70%), secukinumab (~65%), adalimumab (~50%), ustekinumab (~50%)
04
Drug survival (5-year): IL-23 inhibitors and IL-17 inhibitors generally superior to TNF inhibitors and ustekinumab
05
Switching strategy on inadequate response (PASI 75 not achieved at primary endpoint): primary failure → switch class (e.g., TNF → IL-23); secondary failure (initial response then loss) → switch within or across class; intolerance → switch class
06
Treat-to-target: PASI 90 (excellent response) or PASI 100 (clear/almost clear) at 12-16 weeks; DLQI 0/1; assess at 12-16 weeks for primary efficacy, then every 6 months
07
Special situations: scalp psoriasis (IL-17 and IL-23 efficient); palmoplantar (often refractory, IL-23 and IL-17 best); nail psoriasis (12-month assessment, IL-17 and IL-23 effective); pustular and erythrodermic (rapid-acting biologics — bimekizumab, ixekizumab, infliximab IV loading)
08
Combination therapy: biologic + methotrexate (improves drug survival, reduces immunogenicity for TNF inhibitors); avoid combination with cyclosporine for safety
09
Adverse events monitoring: TB reactivation (TNF), Candida (IL-17), serious infections (all), injection site reactions, IBD development with IL-17, malignancy surveillance
10
Pregnancy: certolizumab pegol (TNF, no placental transfer) preferred; ustekinumab and IL-23 inhibitors increasingly used; live vaccinations in infants exposed in utero — caution
11
Pediatric extension: etanercept, adalimumab, ustekinumab, secukinumab, ixekizumab approved for pediatric psoriasis
12
Cost considerations: biosimilars (adalimumab, infliximab, etanercept) reduce cost; access to high-efficacy IL-23/IL-17 may require step-therapy in some health systems
13
Long-term: indefinite therapy in most cases; some achieve sustained remission with risankizumab (~50% at 1 year off-treatment); ongoing monitoring for safety, efficacy, comorbidities

Which Department to Visit?

You can visit our Dermatoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dermatoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Eczema (Atopic Dermatitis)

Dermatoloji

Atopic dermatitis is a chronic skin disease commonly seen especially in children, flaring with genetic predisposition and environmental triggers.

Psoriasis

Dermatoloji

Psoriasis is an autoimmune disease in which skin cells proliferate rapidly when the immune system mistakenly attacks the skin, leading to thick scaly lesions.

Acne

Dermatoloji

Acne is a skin disease resulting from clogging of hair follicles with oil and dead skin cells, commonly seen in adolescence but can occur at any age.

Rosacea

Dermatoloji

Rosacea is a chronic inflammatory facial skin disease characterized by recurrent flushing, persistent erythema, telangiectasia, and inflammatory papules and pustules. Phymatous change and ocular involvement may complicate advanced disease.

Urticaria (Hives)

Dermatoloji

Urticaria is a skin condition with sudden pink-red wheals and intense itching that may follow an acute or chronic course.

Skin Fungal Infections

Dermatoloji

Skin fungal infections are common, contagious skin diseases caused by dermatophytes and yeast fungi colonizing the upper layers of the skin.

Hair Loss (Alopecia)

Dermatoloji

Alopecia is a general term for hair loss that can be genetic, hormonal, autoimmune, or nutritional; early intervention can slow progression.

Vitiligo

Dermatoloji

Vitiligo is an acquired autoimmune disease in which CD8+ T cells destroy melanocytes, producing well-demarcated depigmented patches. Early, sustained treatment can induce repigmentation and prevent progression; psychosocial impact warrants holistic care.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.